Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GPCR | Structure Therapeutics Inc.

Index	-	P/E	-	EPS (ttm)	-2.02	Insider Own	0.10%	Shs Outstand	38.25M	Perf Week	4.72%
Market Cap	1.26B	Forward P/E	-	EPS next Y	-0.97	Insider Trans	0.00%	Shs Float	36.22M	Perf Month	13.97%
Income	-65.50M	PEG	-	EPS next Q	-0.22	Inst Own	41.29%	Short Float / Ratio	6.66% / 5.16	Perf Quarter	16.61%
Sales	-	P/S	-	EPS this Y	-20.70%	Inst Trans	-	Short Interest	2.41M	Perf Half Y	48.98%
Book/sh	5.61	P/B	6.09	EPS next Y	-7.80%	ROA	-	Target Price	48.80	Perf Year	-
Cash/sh	6.10	P/C	5.60	EPS next 5Y	-	ROE	-	52W Range	20.80 - 42.55	Perf YTD	31.50%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-19.65%	Beta	-
Dividend %	-	Quick Ratio	15.20	Sales past 5Y	-	Gross Margin	-	52W Low	64.37%	ATR	1.94
Employees	77	Current Ratio	15.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	60.64	Volatility	6.29% 6.06%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-44.00%	Profit Margin	-	Rel Volume	1.34	Prev Close	34.15
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 10 AMC	Payout	-	Avg Volume	467.46K	Price	34.19
Recom	1.40	SMA20	11.92%	SMA50	9.97%	SMA200	21.27%	Volume	476,647	Change	0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-27-23	Initiated	Piper Sandler	Overweight	$58
May-25-23	Resumed	Jefferies	Buy	$34 → $41
Feb-28-23	Initiated	SVB Securities	Outperform	$33
Feb-28-23	Initiated	Jefferies	Buy	$34
Feb-28-23	Initiated	Guggenheim	Buy	$50
Feb-28-23	Initiated	BMO Capital Markets	Outperform	$40

Aug-10-23 04:05PM	Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Aug-03-23 05:32PM	Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors (GlobeNewswire)
Jul-16-23 07:00AM	Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In. (The Wall Street Journal)
Jun-27-23 02:10PM	Eli Lilly, Pfizer, and Others Are Working on Weight-Loss Pills. What to Know. (Barrons.com) +8.16%
01:35PM	Lilly, Pfizer and Others Are Working on Obesity Pills. What to Know. (Barrons.com)
08:12AM	Loading…
08:12AM	Pfizer Makes a Call on Obesity Pill. Investors Arent Happy. (Barrons.com)
Jun-26-23 09:05PM	Why Shares of Structure Therapeutics Rose Monday (Motley Fool) +18.35%
Jun-16-23 08:00AM	This Biotech Is Developing The Next Ozempic. Should You Buy It? (Motley Fool)
Jun-13-23 06:10AM	Institutional investors own a significant stake of 45% in Structure Therapeutics Inc. (NASDAQ:GPCR) (Simply Wall St.)
Jun-12-23 10:15AM	Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 Years (Motley Fool)
Jun-07-23 08:30AM	Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions (GlobeNewswire)
May-31-23 04:30PM	Structure Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 04:30PM	Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity (GlobeNewswire) +7.94%
May-18-23 04:30PM	Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference (GlobeNewswire)
May-11-23 04:30PM	Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
06:59AM	Loading…
May-03-23 06:59AM	Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-30-23 04:30PM	Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights (GlobeNewswire)
Feb-07-23 04:00PM	Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional American Depositary Shares (GlobeNewswire)
Feb-06-23 03:17PM	The Funded: A solar industry company is on deck to complete the 1st major Bay Area tech IPO in more than a year (American City Business Journals)

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GPCR | Structure Therapeutics Inc.

Upgrade your FINVIZ experience